HomeCompareSYMQY vs BTI

SYMQY vs BTI: Dividend Comparison 2026

SYMQY yields 358.49% · BTI yields 5.38%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 SYMQY wins by $5189.30M in total portfolio value
10 years
SYMQY
SYMQY
● Live price
358.49%
Share price
$0.56
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$5189.33M
Annual income
$3,350,688,442.05
Full SYMQY calculator →
BTI
BTI
● Live price
5.38%
Share price
$58.47
Annual div
$3.15
5Y div CAGR
11.3%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$37.7K
Annual income
$2,786.64
Full BTI calculator →

Portfolio growth — SYMQY vs BTI

📍 SYMQY pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodSYMQYBTI
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, SYMQY + BTI cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
SYMQY pays
BTI pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

SYMQY
Annual income on $10K today (after 15% tax)
$30,471.41/yr
After 10yr DRIP, annual income (after tax)
$2,848,085,175.74/yr
BTI
Annual income on $10K today (after 15% tax)
$457.40/yr
After 10yr DRIP, annual income (after tax)
$2,368.64/yr
At 15% tax rate, SYMQY beats the other by $2,848,082,807.10/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of SYMQY + BTI for your $10,000?

SYMQY: 50%BTI: 50%
100% BTI50/50100% SYMQY
Portfolio after 10yr
$2594.69M
Annual income
$1,675,345,614.34/yr
Blended yield
64.57%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on BTI right now

SYMQY
No analyst data
Altman Z
-15.4
Piotroski
2/9
BTI
Analyst Ratings
12
Buy
4
Hold
2
Sell
Consensus: Buy
Price Target
$40.00
-31.6% upside vs current
Range: $40.00 — $40.00
Altman Z
2.1
Piotroski
7/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

SYMQY buys
0
BTI buys
0
No recent congressional trades found for SYMQY or BTI in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricSYMQYBTI
Forward yield358.49%5.38%
Annual dividend / share$2.00$3.15
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%11.3%
Portfolio after 10y$5189.33M$37.7K
Annual income after 10y$3,350,688,442.05$2,786.64
Total dividends collected$5014.82M$14.3K
Payment frequencyquarterlyquarterly
SectorStockConsumer Staples

Year-by-year: SYMQY vs BTI ($10,000, DRIP)

YearSYMQY PortfolioSYMQY Income/yrBTI PortfolioBTI Income/yrGap
1← crossover$46,549$35,848.72$11,299$598.92+$35.3KSYMQY
2$205,762$155,954.38$12,794$703.91+$193.0KSYMQY
3$864,438$644,273.43$14,518$829.07+$849.9KSYMQY
4$3,454,575$2,529,625.76$16,513$978.64+$3.44MSYMQY
5$13,144,248$9,447,852.61$18,827$1,157.84+$13.13MSYMQY
6$47,660,569$33,596,224.50$21,518$1,373.12+$47.64MSYMQY
7$164,846,065$113,849,255.31$24,657$1,632.46+$164.82MSYMQY
8$544,400,504$368,015,214.66$28,329$1,945.74+$544.37MSYMQY
9$1,718,361,020$1,135,852,481.39$32,637$2,325.33+$1718.33MSYMQY
10$5,189,334,734$3,350,688,442.05$37,708$2,786.64+$5189.30MSYMQY

SYMQY vs BTI: Complete Analysis 2026

SYMQYStock

SymBio Pharmaceuticals Limited engages in the research and development, manufacturing, and marketing of pharmaceutical drugs in the areas of oncology and hematology in Japan. It is involved in the development of Treakisym SyB L-0501, an anti-cancer agent, which is marketed for the treatment of non-Hodgkin's lymphoma, multiple myeloma, and chronic lymphocytic leukemia under the TREAKISYM name; and is in the Phase III clinical trial to treat relapsed/refractory diffuse large B-cell lymphoma. The company also engages in the development of SyB L-1701, a ready-to-dilute formulation; and SyB L-1702, a rapid infusion liquid formulation. In addition, it is involved in the development of SyB L-1101, an intravenous formulation, which is in Phase III clinical trial for the treatment of higher-risk myelodysplastic syndromes (HR-MDS); and SyB C-1101, an oral formulation that is in Phase II/III clinical trial in combination with Azacitidine to treat HR-MDS. Further, it engages in the development of SyB V-1901, an antiviral drug for the treatment of infectious diseases. SymBio Pharmaceuticals Limited was incorporated in 2005 and is based in Tokyo, Japan.

Full SYMQY Calculator →

BTIConsumer Staples

British American Tobacco p.l.c. provides tobacco and nicotine products to consumers in the Americas, Europe, the Asia-Pacific, the Middle East, Africa, and the United States. It offers vapour, heated, and modern oral nicotine products; combustible cigarettes; and traditional oral products, such as snus and moist snuff. The company provides its products under the Vuse, glo, Velo, Grizzly, Kodiak, Dunhill, Kent, Lucky Strike, Pall Mall, Rothmans, Newport, Natural American Spirit, and Camel brands. The company distributes its products to retail outlets. British American Tobacco p.l.c. was founded in 1902 and is based in London, the United Kingdom.

Full BTI Calculator →
📬

Get this SYMQY vs BTI comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

SYMQY vs SCHDSYMQY vs JEPISYMQY vs OSYMQY vs KOSYMQY vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.